GlassScriptPhysician profile
Christine M Curl
NPI 1215124219
$6,745.84
in general payments reported to CMS, 2019-2025
23 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $694 · 2022: $1,126 · 2023: $1,579 · 2024: $1,986 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,761 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,760.91 |
| Education | $164.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,227.66 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $931.44 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $855.68 | 2021-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $662.43 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $503.13 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $396.77 | 2021-2025 | Blu-U |
| Novartis Pharmaceuticals Corporation | $368.86 | 2021-2025 | |
| Genzyme Corporation | $270.64 | 2021-2025 | |
| Pfizer INC. | $248.74 | 2021-2025 | |
| Ucb, INC. | $239.79 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $178.76 | 2022-2024 | Opzelura |
| Leo Pharma INC. | $149.71 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $131.79 | 2022-2024 | Vtama |
| Organogenesis INC. | $127.76 | 2021-2024 | Puraply |
| Regeneron Healthcare Solutions, INC. | $110.67 | 2021-2023 | Libtayo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $93.12 | 2023-2025 | Vtama, Hadlima |
| Convatec INC. | $73.36 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.60 | 2023-2024 | Spevigo |
| Almirall LLC | $46.35 | 2021 | |
| Mayne Pharma Commercial LLC | $19.37 | 2023 | |
| Journey Medical Corporation | $18.04 | 2025 | |
| Galderma Laboratories, L.P. | $15.87 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $13.30 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Curl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.